Literature DB >> 26939935

Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.

H Schaballie1,2, G Wuyts2, D Dillaerts2, G Frans2,3, L Moens2, M Proesmans1, F Vermeulen1, K De Boeck1, I Meyts1,2, X Bossuyt2,3.   

Abstract

During the past 10 years, pneumococcal conjugate vaccine (PCV) has become part of the standard childhood vaccination programme. This may impact upon the diagnosis of polysaccharide antibody deficiency by measurement of anti-polysaccharide immunoglobulin (Ig)G after immunization with unconjugated pneumococcal polysaccharide vaccine (PPV). Indeed, contrary to PPV, PCV induces a T-dependent, more pronounced memory response. The antibody response to PPV was studied retrospectively in patients referred for suspected humoral immunodeficiency. The study population was divided into four subgroups based on age (2-5 years versus ≥ 10 years) and time tested (1998-2005 versus 2010-12). Only 2-5-year-old children tested in 2010-12 had been vaccinated with PCV prior to PPV. The PCV primed group showed higher antibody responses for PCV-PPV shared serotypes 4 and 18C than the unprimed groups. To a lesser extent, this was also found for non-PCV serotype 9N, but not for non-PCV serotypes 19A and 8. Furthermore, PCV-priming elicited a higher IgG2 response. In conclusion, previous PCV vaccination affects antibody response to PPV for shared serotypes, but can also influence antibody response to some non-PCV serotypes (9N). With increasing number of serotypes included in PCV, the diagnostic assessment for polysaccharide antibody deficiency requires careful selection of serotypes that are not influenced by prior PCV (e.g. serotype 8). Further research is needed to identify more serotypes that are not influenced.
© 2016 British Society for Immunology.

Entities:  

Keywords:  pneumococcal conjugate vaccine; polysaccharide antibody deficiency; specific antibody deficiency; unconjugated pneumococcal polysaccharide vaccine

Mesh:

Substances:

Year:  2016        PMID: 26939935      PMCID: PMC4955003          DOI: 10.1111/cei.12784

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

Review 1.  Vaccines in the assessment of patients for immune deficiency.

Authors:  Mark Ballow
Journal:  J Allergy Clin Immunol       Date:  2012-07       Impact factor: 10.793

2.  Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization.

Authors:  P V Licciardi; A Balloch; F M Russell; E K Mulholland; M L K Tang
Journal:  Vaccine       Date:  2010-03-31       Impact factor: 3.641

3.  Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.

Authors:  Andrés de Roux; B Schmöle-Thoma; B Schmöele-Thoma; G R Siber; J G Hackell; A Kuhnke; N Ahlers; S A Baker; A Razmpour; E A Emini; P D Fernsten; W C Gruber; S Lockhart; O Burkhardt; T Welte; H M Lode
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

Review 4.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

5.  Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood.

Authors:  M Anttila; J Eskola; H Ahman; H Käyhty
Journal:  Vaccine       Date:  1999-04-09       Impact factor: 3.641

6.  Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine.

Authors:  S Zielen; I Bühring; N Strnad; J Reichenbach; D Hofmann
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants.

Authors:  S Choo; L Seymour; R Morris; S Quataert; S Lockhart; K Cartwright; A Finn
Journal:  Pediatr Infect Dis J       Date:  2000-09       Impact factor: 2.129

8.  Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.

Authors:  Philippe Lesprit; Gaëlle Pédrono; Jean-Michel Molina; Cécile Goujard; Pierre-Marie Girard; Nathalie Sarrazin; Christine Katlama; Patrick Yéni; Pascale Morineau; Jean-François Delfraissy; Geneviève Chêne; Yves Lévy
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

9.  Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults.

Authors:  D C Powers; E L Anderson; K Lottenbach; C M Mink
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

10.  Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.

Authors:  Lindsay R Grant; Sarah E O'Brien; Polly Burbidge; Mitch Haston; Marta Zancolli; Lucy Cowell; Marina Johnson; Robert C Weatherholtz; Raymond Reid; Mathuram Santosham; Katherine L O'Brien; David Goldblatt
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

View more
  6 in total

1.  Defining Polysaccharide Antibody Deficiency: Measurement of Anti-Pneumococcal Antibodies and Anti-Salmonella typhi Antibodies in a Cohort of Patients with Recurrent Infections.

Authors:  Giorgia Bucciol; Heidi Schaballie; Rik Schrijvers; Barbara Bosch; Marijke Proesmans; Kris De Boeck; Mieke Boon; François Vermeulen; Natalie Lorent; Doreen Dillaerts; Bjørn Kantsø; Charlotte Svaerke Jørgensen; Marie-Paule Emonds; Xavier Bossuyt; Leen Moens; Isabelle Meyts
Journal:  J Clin Immunol       Date:  2019-11-08       Impact factor: 8.542

2.  Fifth Percentile Cutoff Values for Antipneumococcal Polysaccharide and Anti-Salmonella typhi Vi IgG Describe a Normal Polysaccharide Response.

Authors:  Heidi Schaballie; Barbara Bosch; Rik Schrijvers; Marijke Proesmans; Kris De Boeck; Mieke Nelly Boon; François Vermeulen; Natalie Lorent; Doreen Dillaerts; Glynis Frans; Leen Moens; Inge Derdelinckx; Willy Peetermans; Bjørn Kantsø; Charlotte Svaerke Jørgensen; Marie-Paule Emonds; Xavier Bossuyt; Isabelle Meyts
Journal:  Front Immunol       Date:  2017-05-12       Impact factor: 7.561

3.  Rapid kinetics of serum IgA after vaccination with Prevnar®13 followed by Pneumovax®23.

Authors:  Rebecca R Crowther; Christine M Collins; Cheryl Conley; Osvaldo J Lopez
Journal:  Heliyon       Date:  2017-02-22

4.  Measurement of Typhim Vi IgG as a Diagnostic Tool to Determine Anti-polysaccharide Antibody Production Deficiency in Children.

Authors:  Kissy Guevara-Hoyer; Celia Gil; Antony R Parker; Leigh J Williams; Carmen Orte; Antonia Rodriguez de la Peña; Juliana Ochoa-Grullón; Edgard Rodriguez De Frias; Irene Serrano García; Sonia García-Gómez; M José Recio; Miguel Fernández-Arquero; Rebeca Pérez de Diego; Jose Tomas Ramos; Silvia Sánchez-Ramón
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

5.  A Critical View of Specific Antibody Deficiencies.

Authors:  Ricardo U Sorensen
Journal:  Front Immunol       Date:  2019-05-01       Impact factor: 7.561

6.  Molecular surveillance of pneumococcal carriage following completion of immunization with the 13-valent pneumococcal conjugate vaccine administered in a 3 + 1 schedule.

Authors:  George A Syrogiannopoulos; Ioanna N Grivea; Maria Moriondo; Francesco Nieddu; Aspasia N Michoula; Maria Rita Calabrese; Michael Anthracopoulos; Chiara Azzari
Journal:  Sci Rep       Date:  2021-12-30       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.